Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Increases By 125.0%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 900 shares, a growth of 125.0% from the June 30th total of 400 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 6,500 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Fidelity Disruptive Medicine ETF stock. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 12.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 688,750 shares of the company’s stock after purchasing an additional 76,538 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 31.31% of Fidelity Disruptive Medicine ETF worth $16,544,000 as of its most recent filing with the SEC.

Fidelity Disruptive Medicine ETF Price Performance

NASDAQ FMED opened at $23.89 on Thursday. The firm’s 50-day moving average is $23.74 and its two-hundred day moving average is $24.15. Fidelity Disruptive Medicine ETF has a 12 month low of $20.69 and a 12 month high of $26.79. The stock has a market capitalization of $52.56 million, a P/E ratio of 41.33 and a beta of 1.01.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.